Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
1. A method of increasing by at least 3% the lean body mass or the lean body mass/fat mass ratio in a subject having Prader-Willi Syndrome (PWS) or Smith-Magenis syndrome (SMS), said method comprising administering once daily to said subject effective amount of a K ATP channel opener, or a pharmaceutically acceptable salt thereof;
wherein said K ATP channel opener is diazoxide or a pharmaceutically acceptable salt thereof;
wherein said K ATP channel opener, or a pharmaceutically acceptable salt thereof is formulated as an oral controlled release pharmaceutical composition;
wherein the administration of the K ATP channel opener is sufficient to increase the lean body mass or lean body mass/fat mass ratio of the subject by at least 3% compared to the lean body mass or lean body mass/fat mass ratio of the subject prior to the start of the administration; and
wherein the subject's circulating ghrelin level is reduced by at least 15% after at least 10 weeks of administering the diazoxide, or a pharmaceutically acceptable salt thereof.
2. A method of increasing by at least 3% the lean body mass or the lean body mass/fat mass ratio in a subject having Prader-Willi Syndrome (PWS) or Smith-Magenis syndrome (SMS), said method comprising administering once daily to said subject effective amount of a K ATP channel opener, or a pharmaceutically acceptable salt thereof;
wherein said K ATP channel opener is diazoxide or a pharmaceutically acceptable salt thereof;
wherein said K ATP channel opener, or a pharmaceutically acceptable salt thereof is formulated as an oral controlled release pharmaceutical composition;
wherein the administration of the K ATP channel opener is sufficient to increase the lean body mass or lean body mass/fat mass ratio of the subject by at least 3% compared to the lean body mass or lean body mass/fat mass ratio of the subject prior to the start of the administration; and
wherein the subject's circulating total cholesterol level is reduced by at least 4% after at least 10 weeks of administering the diazoxide, or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , wherein the subject's circulating total cholesterol level comprises circulating high-density lipoprotein cholesterol (HDL-C) and wherein the subject's circulating HDL-C level is increased by at least 25% after at least 10 weeks of administering the diazoxide, or a pharmaceutically acceptable salt thereof.
4. The method of claim 2 , wherein the subject's circulating total cholesterol level comprises circulating low-density lipoprotein cholesterol (LDL-C) and wherein the subject's circulating LDL-C level is reduced by at least 7% after at least 10 weeks of administering the diazoxide, or a pharmaceutically acceptable salt thereof.
5. The method of claim 2 , wherein the subject's circulating total cholesterol level comprises circulating non-high-density lipoprotein cholesterol (non-HDL-C) and wherein the subject's circulating non-HDL-C level is reduced by at least 13% after at least 10 weeks of administering the diazoxide, or a pharmaceutically acceptable salt thereof.